Ioflupane (123i) Rotop (Ioflupane (123i))

After intravenous injection, Ioflupane binds selectively to dopamine transporters on neuronal membranes. The attached radioactive iodine emits gamma photons that are captured by a SPECT scanner, producing images that reflect the density and functional status of dopaminergic pathways.

The administered activity of Ioflupane is determined by the prescribing physician or nuclear medicine specialist. Dosing is individualized based on patient weight, imaging protocol, and regulatory guidelines, and is not standardized across all patients.

Safety data for Ioflupane in pregnant or lactating women are limited. It is classified as having unknown risk, and use is generally avoided unless the diagnostic benefit outweighs potential fetal or infant exposure. Consultation with a specialist is essential.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

Ioflupane is chemically identical to the FDA‑approved DaTscan and provides high‑resolution DAT imaging. Compared with non‑specific brain perfusion agents, Ioflupane offers superior specificity for dopaminergic neurons, allowing more accurate differentiation of Parkinsonian syndromes from other movement disorders.

The product must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. It should be kept in its original container until use, and any unused portion should be discarded according to local radiopharmaceutical waste regulations.

Ioflupane is administered as a single intravenous injection by a qualified nuclear medicine professional. After injection, a waiting period of about 3–6 hours is typical before SPECT imaging to allow optimal tracer uptake and clearance of background activity.

Serious risks include severe allergic reactions such as anaphylaxis, significant hypotension, radiation‑induced skin injury at the injection site, and rare cardiac arrhythmias. Patients should be monitored during and after administration, and any adverse event should be reported promptly.

Ioflupane is contraindicated in individuals with known hypersensitivity to Ioflupane or any excipients in the formulation. It should also be avoided in pregnant women unless absolutely necessary, and used with caution in patients with severe renal impairment or those receiving interfering medications.